Extracellular matrix calcification in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 4, 2011, Pages 360-368

  Toussaint, Nigel D ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

calcification; chronic kidney disease; extracellular matrix; mineral metabolism; vascular calcification

Indexed keywords

ALENDRONIC ACID; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; FIBROBLAST GROWTH FACTOR 23; INTERMEDIN; INTERSTITIAL COLLAGENASE; OSTEOPROTEGERIN; PHOSPHATE; PLACEBO; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; SECRETED FRIZZLED RELATED PROTEIN 4; STROMELYSIN; TRANSGELIN; VITAMIN D;

ARTERY CALCIFICATION; BLOOD VESSEL CALCIFICATION; BONE TURNOVER; CALCIFICATION; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY ARTERY CALCIFICATION; DISEASE SEVERITY; DRUG EFFICACY; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX CALCIFICATION; HUMAN; KIDNEY FUNCTION; LOW DRUG DOSE; MINERAL METABOLISM; NONHUMAN; OSTEOBLAST; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD VESSELS; CALCINOSIS; CHRONIC DISEASE; EXTRACELLULAR MATRIX; HUMANS; KIDNEY DISEASES; VASCULAR DISEASES;

EID: 79958838364     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283479330     Document Type: Review

References (79)

1. London GM, Guerin AP, Marchais S, et al. Arterial media calcification in endstage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18:1731-1740. (Pubitemid 37098542)
2. Rennenberg RJ, Kessels AG, Schurgers LJ, et al. Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag 2009; 5:185-197.
3. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients. J Am Soc Nephrol 2009; 20:1453-1464.
4. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008; 117:2938-2948. (Pubitemid 351787058)
5. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 2010; 7:528-536.
6. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478-1483. (Pubitemid 30318271)
7. Foley RN, Parfrey PS. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998; 32 (Suppl 3):S112-S119. (Pubitemid 28527268)
8. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
9. Moe SM, O'Neill KD, Reslerova M, et al. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 2004; 19: 2387-2393. (Pubitemid 39214138)
10. Amann K. Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3:1599-1605.
11. Duhn V, D'Orsi ET, Johnson S, et al. Breast arterial calcification: a marker of medial vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:377-382.
12. Shroff RC, Donald AE, Hiorns MP, et al. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 2007; 18:2996-3003. (Pubitemid 350058407)
13. Hanada S, Ando R, Naito S, et al. Assessment and significance of abdominal aortic calcification in chronic kidney disease. Nephrol Dial Transplant 2010; 25:1888-1895.
14. Temmar M, Liabeuf S, Renard C, et al. Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertens 2010; 28:163-169.
15. Chiu YW, Adler SG, Budoff MJ, et al. Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int 2010; 77:1107-1114.
16. Russo D, Corrao S, Miranda I, et al. Progression of coronary artery calcification in predialysis patients. Am J Nephrol 2007; 27:152-158. (Pubitemid 46588180)
17. Tomiyama C, Carvalho AB, Higa A, et al. Coronary artery calcification is associated with lower bone formation rate in CKD patients not yet on dialysis treatment. J Bone Miner Res 2010; 25:499-504.
18. Mohler ER 3rd,Gannon F, Reynolds C, et al. Bone formation and inflammation in cardiac valves. Circulation 2001; 103:1522-1528. (Pubitemid 32226259)
19. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 2005; 97:105-114. (Pubitemid 41033466)
20. Proudfoot D, Skeeper JN, Hegyi L, et al. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000; 87:1055-1062.
21. Hosaka N, Mizobuchi M, Ogata H, et al. Elastin degradation accelerates phosphate-induced mineralization of vascular smooth muscle cells. Calcif Tissue Int 2009; 85:523-529.
22. Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005; 67:2295-2304. (Pubitemid 41623389)
23. Li X, Giachelli CM. Sodium-dependent phosphate co-transporters and vascular calcification. Curr Opin Nephrol Hypertens 2007; 16:325-328. (Pubitemid 46944330)
24. Schlieper G, Aretz A, Verberckmoes SC, et al. Ultrastructural analysis of vascular calcification in uremia. J Am Soc Nephrol 2010; 21:689-696.
25. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of smooth muscle cell calcification. Circ Res 2000; 87:E10-E17.
26. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15:2857-2867. (Pubitemid 41103395)
27. Shroff RC, McNair R, Figg N, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008; 118:1748-1757.
28. Moe SM, Duan D, Doehle BP, et al. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 2003; 63:1003-1011. (Pubitemid 36315578)
29. Shroff RC, McNair R, Skepper JN, et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 2010; 21:103-112.
30. Speer M, Yang H, Brabb T, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 2009; 104:733-741.
31. Neven E, Persy V, Dauwe S, et al. Chondrocyte rather than osteoblast conversion of vascular cells underlies medial calcification in uremic rats. Arterioscler Thromb Vasc Biol 2010; 30:1741-1750.
32. Román-García P, Carrillo-Ló pez N, Fernández-Martín J, et al. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 2010; 46: 121-128.
33. Montes de Oca A, Madueno JA, Martinez-Moreno JM, et al. High-phosphateinduced calcification is related to SM22a promoter methylation in vascular smooth muscle cells. J Bone Min Res 2010; 25:1996-2005.
34. Giachelli CM, Speer MY, Li X, et al. Regulation of vascular calcification: roles of phosphate and osteopontin. Cir Res 2005; 96:717-722. (Pubitemid 40559510)
35. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008; 19:213-216. (Pubitemid 351240642)
36. Yoshida H, Yokoyama K, Yaginuma T, et al. Difference in coronary artery intima and media calcification in autopsied patients with chronic kidney disease. Clin Nephrol 2011; 75:1-7.
37. Lau WL, Festing MH, Giachelli CM. Phosphate and vascular calcification: emerging role of the sodium-dependent phosphate co-transporter PiT-1.
38. Villa-Bellosta R, Levi M, Sorribas V. Vascular smooth muscle cell calcification and SLC20 inorganic phosphate transporters: effects of PDGF, TNF-a, and Pi. Pflugers Arch 2009; 458:1151-1161.
39. Ohnishi M, Nakatani T, Lanske B, Razzaque MS. In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25 dihydroxyvitamin D levels. Cir Cardiovasc Genet 2009; 2:583-590.
40. Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22:124-136.
41. Nabeshima Y, Imura H. Alpha-Klotho: a regulator that integrates calcium homeostasis. Am J Nephrol 2008; 28:455-464. (Pubitemid 351501612)
42. Proudfoot D, Shanahan CM. Molecular mechanisms mediating vascular calcification: role of matrix Gla protein. Nephrology (Carlton) 2006; 11: 455-461. (Pubitemid 44470096)
43. Alam M, Kirton JP, Wilkinson FL, et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 2009; 81:260-268.
44. Pai AS, Giachelli CM. Matrix remodelling in vascular calcification associated with chronic kidney disease. J Am Soc Nephrol 2010; 21:1637-1640.
45. Maeda S, Hayashi M, Komiya S, et al. Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J 2004; 23:552-563. (Pubitemid 38282387)
46. Aikawa E, Aikawa M, Lippy P, et al. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 2009; 119:1785-1794.
47. Cozzolino M, Biondi ML, Galassi A, et al. Vascular calcification and cardiovascular outcome in dialysis patients: the role of gene polymorphisms. Blood Purif 2010; 29:347-351.
48. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77:863-878.
49. Cozzolino M, Biondi ML, Galassi A, et al. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with mortality in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2207-2212.
50. Basalyga DM, Simionescu DT, Xiong W, et al. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation 2004; 110:3480-3487. (Pubitemid 39602227)
51. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodelling and vascular disease. Biochem Pharmacol 2008; 75: 346-359. (Pubitemid 350298459)
52. Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin-A. Kidney Int 2005; 67:2383-2392. (Pubitemid 41623401)
53. Wang AY, Woo J, Lam CW, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20:1676-1685. (Pubitemid 41418594)
54. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361:827-833. (Pubitemid 36331846)
55. Hermans MMH, Brandenburg V, Ketteler M, et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 2006; 21:1293-1299.
56. Mehrotra R, Westenfeld R, Christenson P, et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 2005; 67:1070-1077. (Pubitemid 41623332)
57. Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant 2006; 21:1915-1920. (Pubitemid 43985720)
58. Hamano T, Matsui I, Mikami S, et al. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 2010; 21: 1998-2007.
59. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009; 204:321-329.
60. Nitta K, Akiba T, Uchida K, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003; 42:303-309. (Pubitemid 36944438)
61. Mikami S, Hamano T, Fujii N, et al. Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients. Hypertens Res 2008; 31:1163-1170.
62. Speer G, Fekete BC, El Hadj Othmane T, et al. Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. Nephrol Dial Transplant 2008; 23:3256-3262.
63. Sigrist MK, Levin A, McIntyre CW. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant 2009; 24:3157-3162.
64. Nakashima A, Carrero JJ, Qureshi AR, et al. Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. Osteopor Int 2010 [Epub ahead of print].
65. Morena M, Terrier N, Jaussent I, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006; 17:262-270.
66. Hermans MMH, Vermeer C, Kooman JP, et al. Undercarboxylated matrix Gla protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Blood Purif 2007; 25:395-401. (Pubitemid 351194878)
67. Cranenburg EC, Brandenburg VM, Vermeer C, et al. Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost 2009; 101:359-366.
68. Lomashvili K, Cobbs S, Hennigar R, et al. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol 2004; 15:1392-1401. (Pubitemid 38679664)
69. O'Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant 2010; 25:187-191.
70. Schurgers LJ, Barreto DV, Barreto FC, et al. The circulating inactive form of matrix Gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 2010; 5:568-575.
71. Lopez I, Aguilera-Tejero E, Mendoza FJ, et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006; 17:795-804.
72. Lopez I, Mendoza FJ, Aguilera-Tejero E, et al. The effect of calcitriol, paricalcitol and calcimimetic AMG-641 on extraosseous calcifications in uremic rats. Kidney Int 2008; 73:300-307.
73. Cunningham J, Danese M, Olsen K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800. (Pubitemid 43169924)
74. Ohanian J, Gatfield KM, Ward DT, Ohanian V. Evidence for a functional calcium-sensing receptor that modulates myogenic tone in rat subcutaneous small arteries. Am J Physiol Heart Circ Physiol 2005; 288:H1756-H1762. (Pubitemid 40418001)
75. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26:1327-1339.
76. Cai Y, Xu MJ, Teng X, et al. Intermedin inhibits vascular calcification by increasing the level of matrix gamma-carboxyglutamic acid protein. Cardiovasc Res 2010; 85:864-873.
77. O'Neill WC, Lomashvili KA, Malluche HH, et al. Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int 2011; 79:490-493.
78. Toussaint ND, Lau KK, Strauss BJ, et al. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled study. Am J Kidney Dis 2010; 56:57-68.
79. O'Neill WC, Lomashvili KA. Recent progress in the treatment of vascular calcification. Kidney Int 2010; 78:1232-1239.